The Gene Therapy stream features two back-to-back conferences looking at the critical challenges facing the analytics, quality control and commercialization of vector-based and cell-based gene therapies, with dedicated sessions on AAV and lentivirus-based platforms as well as oncolytic viruses and gene editing therapies.
The first part of the week, Gene Therapy CMC and Analytics, looks at building an effective CMC development strategy followed by gene therapy potency assessment, stability, comparability and quality control. Part two, Gene Therapy Bioproduction, focuses on largescale AAV and lentivirus process development, formulation, scale-up, product lifecycle management, industrialization and facility design and regulatory compliance.
2017 GENE THERAPY TRACKS
Gene Therapy CMC & Analytics
Gene Therapy Bioproduction